Drug Profile
VRC-HIVADV038-00-VP
Alternative Names: HIV vaccine rAd5-Env-A VRC; rAd5 HIV vaccine VRC Env-A; rAd5-EnvA vaccine; VRC-rAd5 HIV vaccine Env-ALatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator GenVec; National Institute of Allergy and Infectious Diseases
- Developer National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention, In volunteers) in USA (IM, Injection)
- 01 May 2014 National Institute of Allergy and Infectious Diseases completes a phase I trial in HIV-1 infection (prevention, in volunteers) in USA (NCT00479999)